Skip to main content
Reagents

葡萄糖酶法检测试剂（Cliniqa R84682）

Composition
源方案列出的Glucose Reagent 1和Glucose Reagent 2，目录号R84682。
Use information
Cobas Mira Plus葡萄糖酶法检测的液体反应试剂。

Published protocol versions

  • 血液葡萄糖浓度酶法测定 · Sample Handling as performed by the Cobas Mira Plus. · 葡萄糖酶法反应试剂 100 µL · Cliniqa R84682；对应源材料中的Glucose Reagent 1/2，不推断瓶间配比。

    Source version：protocols.io · vv1 · John Stack; Gary Cline · This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

    high-fat diet plus streptozotocin-induced type 2 diabetes mouse · Verified applicability · 糖尿病模型（NIDDM mice were compared with chow-fed wild-type controls; fasting glucose, urine protein, histology and FNDC5/PGC1alpha staining were assessed.；Verified applicability） · 代谢疾病（高脂饮食联合链脲佐菌素 2 型糖尿病小鼠（品系未报到实体粒度）：用于部分 β 细胞损伤叠加胰岛素抵抗的糖尿病研究。；Verified applicability）
    BioBreeding (BB) rat · Verified applicability · 糖尿病模型（BB rats model spontaneous autoimmune diabetes but carry lymphopenia absent in human T1D.；Verified applicability） · 糖尿病肾病 (DN)（BB 大鼠：自发 1 型糖尿病肾小球病变（综述推荐）；Verified applicability）
    high-fat diet plus low-dose streptozotocin-induced type 2 diabetes Sprague-Dawley rat · Verified applicability · 糖尿病模型（Type 2 diabetic osteoporosis model compared with sham and with streptozotocin-diabetic Belgrade rats.；Verified applicability） · 2型糖尿病 (T2D)（Whether DMT1-mediated iron transport in bone contributes to the bone microstructure and biomechanical deterioration of type 2 diabetic osteoporosis.; Tibia of male Sprague-Dawley rats, 3 months old at purchase, fed high-fat diet for two months then given 30 mg/kg intraperitoneal streptozotocin, studied at 8 months of age; n=10 per group.；Verified applicability）
    high-fat diet-induced obesity and diabetes C57BL/6J mouse · Verified applicability · 糖尿病模型（HFD-fed mice developed glucose intolerance, insulin resistance, fasting hyperglycaemia and dyslipidaemia, and noise exposure accelerated these changes.；Verified applicability） · 2型糖尿病 (T2D)（Does liver-directed AAV-BMP7 reverse diet-induced obesity and insulin resistance?; Male C57BL/6J mice fed chow or HFD for 6 weeks from 2 months of age, then followed about 6 months；Verified applicability）
    NOD mouse · Verified applicability · 糖尿病模型（NOD mice with slow insulitis development were compared with BDC2.5/NOD mice to identify paths associated with early insulitis.；Verified applicability） · 糖尿病肾病 (DN)（NOD 小鼠：自身免疫 1 型糖尿病伴肾小球 PAS 病变（综述推荐）；Verified applicability）
    db/db mouse · Verified applicability · 糖尿病模型（db/db mice were compared with db/+ controls and with the STZ-HFD model.；Verified applicability） · 代谢疾病（db/db 小鼠（背景未报到实体粒度）：Lepr db/db 瘦素受体功能缺陷，用于遗传性肥胖与 2 型糖尿病研究。；Verified applicability） · 2型糖尿病 (T2D)（Which metabolic and renal abnormalities develop in db/db mice; kidney tissue, urine and serum from db/db mice；Verified applicability） · 糖尿病肾病 (DN)（db/db 小鼠（背景按各研究记载）：白蛋白尿与肾小管线粒体损伤读出；Verified applicability）
    NOD/ShiLtJ mouse · Verified applicability · 糖尿病模型（Mice developed diabetes spontaneously; diabetic and nondiabetic mice were compared.；Verified applicability）
    streptozotocin-induced diabetes Sprague-Dawley rat · Verified applicability · 糖尿病模型（Diabetes induced with a single intraperitoneal STZ injection, then insulin withdrawn in the DKA group to produce ketoacidosis.；Verified applicability）
    streptozotocin-induced diabetes rat · Verified applicability · 糖尿病模型（The review presents the streptozotocin rat as a classic model with reduced nerve fiber, axon and myelin size, but notes it was not validated with antineuropathic drugs.；Verified applicability）
    Zucker diabetic fatty (ZDF) rat · Verified applicability · 糖尿病模型（Review of progressive albuminuria and renal lesions in ZDF rats.；Verified applicability） · 代谢疾病（ZDF 大鼠：Lepr fa/fa 纯合糖尿病脂肪大鼠，用于肥胖伴显性糖尿病研究。；Verified applicability） · 2型糖尿病 (T2D)（Review of pancreatic, renal, ocular, neural, bone and gonadal complications in obese T2D rat models.; Review-level synthesis of ZDF studies.；Verified applicability） · 糖尿病肾病 (DN)（ZDF 大鼠：高脂喂养诱导的 2 型糖尿病肾渐进性病变（综述汇总）；Verified applicability）
    Akita C57BL/6 mouse · Verified applicability · 糖尿病模型（The Ins2 Akita model develops beta-cell depletion and diabetic nephropathy.；Verified applicability）
    high-fat diet plus low-dose streptozotocin-induced type 2 diabetes Wistar rat · Verified applicability · 糖尿病模型（The diabetic group (n = 40) received high-fat diet and low-dose streptozotocin to induce type 2 diabetes, then underwent wounding procedures.；Verified applicability） · 2型糖尿病 (T2D)（Does MOTS-c restore cardiac mitochondrial respiration in type 2 diabetic rats?; Male Wistar rats, 6-7 weeks old and 150-200 g, fed a high-fat diet for 15 weeks with a 25 mg/kg streptozotocin injection at week 8；Verified applicability）
    streptozotocin-induced diabetes Wistar rat · Verified applicability · 糖尿病模型（Streptozotocin-induced diabetic Wistar rats were used to examine retinal rhodopsin generation and the development of diabetic retinopathy.；Verified applicability）
    ob/ob BTBR mouse · Verified applicability · 糖尿病模型（BTBR ob/ob mice are described as a robust progressive DN model with severe type 2 diabetes and renal damage.；Verified applicability） · 2型糖尿病 (T2D)（Which rodent models and phenotyping methods are appropriate for experimental diabetic nephropathy?; diabetic nephropathy models；Verified applicability） · 糖尿病肾病 (DN)（BTBR ob/ob 小鼠：渐进白蛋白尿、GBM 增厚与系膜基质扩张的 2 型 DN 模型；Verified applicability）
    streptozotocin-induced diabetes DBA/2 mouse · Verified applicability · 糖尿病模型（Review of strain-dependent albuminuria and mortality.；Verified applicability）
    KK-Ay mouse · Verified applicability · 糖尿病模型（Review of glomerular pathology in KK-Ay mice.；Verified applicability） · 2型糖尿病 (T2D)（What stages of diabetic nephropathy does the KK-Ay mouse reproduce?; KK-Ay mouse；Verified applicability） · 糖尿病肾病 (DN)（KK-Ay 小鼠：肥胖胰岛素抵抗伴 KIM-1 相关小管脂质摄取与 DKD 进展；Verified applicability）
    Spontaneously Diabetic Torii (SDT) fatty rat · Verified applicability · 糖尿病模型（The review recommends SDT fatty rats for studying pathogenesis and screening antidiabetic peripheral neuropathic drugs, particularly for type 2 diabetes.；Verified applicability） · 2型糖尿病 (T2D)（Pathophysiological features of diabetes and its complications in obese T2D rat models.; Review-level synthesis across models.；Verified applicability）
    t2dn/mcwi rat · Verified applicability · 糖尿病模型（Review of glomerulosclerosis and proteinuria in the T2DN/Mcwi substrain.；Verified applicability） · 2型糖尿病 (T2D)（Is the T2DN/Mcwi rat suitable for advanced diabetic nephropathy research?; T2DN/Mcwi rat；Verified applicability）
    spontaneous autoimmune type 1 diabetes LEW.1AR1-IDDM rat · Verified applicability · 糖尿病模型（LEW rats provide a congenic spontaneous autoimmune T1D model with a short pre-diabetic period.；Verified applicability）
    alloxan-induced diabetes rat · Verified applicability · 糖尿病模型（Alloxan-induced diabetic rats are a chemical model of insulin-deficient diabetes used in diabetic neuropathy research; the cited review notes that alloxan is now less commonly used than streptozotocin.；Verified applicability） · 糖尿病肾病 (DN)（四氧嘧啶糖尿病大鼠：白蛋白尿与肾小球病变（综述记载）；Verified applicability）
    高脂饮食代谢模型（C57BL/6背景） · Verified applicability · 糖尿病模型（HFD-fed wild-type mice were compared with normal-diet controls and with ob/ob and DKO mice.；Verified applicability）
    OVE26 transgenic diabetic mouse · Verified applicability · 糖尿病模型（The review lists OVE26 as a T1D model based on beta-cell calmodulin overexpression.；Verified applicability） · 糖尿病肾病 (DN)（OVE26 转基因糖尿病小鼠：足细胞形态与转录改变、肾小球超微结构病变；Verified applicability）
    Spontaneously Diabetic Torii (SDT) rat · Verified applicability · 糖尿病模型（Review states that SDT rats most closely resemble human pathophysiology but lack microaneurysms.；Verified applicability） · 代谢疾病（SDT 大鼠：Sprague-Dawley 来源自发性糖尿病大鼠，用于 2 型糖尿病及并发症研究。；Verified applicability） · 2型糖尿病 (T2D)（Which rat model most closely resembles human DR pathophysiology?; Review of spontaneously diabetic Torii rats；Verified applicability）
    Otsuka Long-Evans Tokushima Fatty (OLETF) rat · Verified applicability · 糖尿病模型（The review considers OLETF rats a better type 2 diabetic neuropathy model than LETO rats.；Verified applicability） · 代谢疾病（OLETF 大鼠：CCK1 受体缺失突变的自发性多基因代谢综合征大鼠，用于肥胖与 2 型糖尿病研究。；Verified applicability） · 2型糖尿病 (T2D)（Recommendation that diabetic rat models remain essential for developing novel drugs and understanding human diabetes.; Review-level conclusion.；Verified applicability） · 糖尿病肾病 (DN)（OLETF 大鼠：自发 2 型糖尿病肾大球硬化与小管间质纤维化（综述推荐）；Verified applicability）
    spontaneously diabetic wbn/kob rat · Verified applicability · 糖尿病模型（The review recommends WBN/Kob rats as a better model for human peripheral diabetic neuropathy because of primary segmental demyelination and secondary axonal degeneration.；Verified applicability）
    streptozotocin-induced diabetes C57BL/6J mouse · Verified applicability · 糖尿病模型（STZ 50 mg/kg daily for 5 days; dorsal full-thickness wounds; DSCG or SP treatment.；Verified applicability） · 糖尿病肾病 (DN)（STZ 糖尿病 C57BL/6J 小鼠：肾小管损伤与足细胞表型读出；Verified applicability）
    high-fat diet-induced obesity mouse · Verified applicability · 糖尿病模型（Y5 was given subcutaneously every 3 days at 25, 50 or 75 nmol/kg.；Verified applicability） · 2型糖尿病 (T2D)（Whether PTPN1/PTPN2 inhibition induces weight loss in diet-induced obesity with an intact but resistant leptin axis; DIO mice, n = 5 per group, 6-week treatment plus 2-week withdrawal；Verified applicability）
    ob/ob mouse · Verified applicability · 糖尿病模型（ob/ob mice were injected with Lpcat3 or control ASO twice weekly for 5 weeks.；Verified applicability） · 代谢疾病（ob/ob 小鼠（背景未报到实体粒度）：Lep 配体缺失性遗传肥胖，用于瘦素通路与能量代谢研究。；Verified applicability） · 2型糖尿病 (T2D)（Does suppressing Lpcat3 improve insulin resistance and lipid metabolism in diet-induced and genetic obese diabetic mice?; 6-7-week-old ob/ob mice；Verified applicability）
    high-fat diet plus streptozotocin-induced type 2 diabetes C57BL/6 mouse · Verified applicability · 糖尿病模型（Mice received 4-6 weeks of 60% kcal fat diet then one 100 mg/kg STZ dose and 12 further weeks of HFD.；Verified applicability） · 2型糖尿病 (T2D)（Does the STZ-HFD model produce more intervertebral disc inflammation and degeneration than db/db?; Intervertebral discs from male C57BL/6 mice, 12 weeks old at start, n=13 STZ-HFD and n=7 vehicle controls；Verified applicability） · 糖尿病肾病 (DN)（HFD+STZ C57BL/6 小鼠：肾损伤与线粒体动力学终点；Verified applicability）
    streptozotocin-induced diabetes mouse · Verified applicability · 糖尿病模型（Review concludes that most available models represent NPDR rather than PDR.；Verified applicability） · 糖尿病肾病 (DN)（STZ 诱导糖尿病小鼠（品系按研究记载）：白蛋白尿、GBM 增厚与系膜基质扩增；Verified applicability）
    university of california davis type 2 diabetes mellitus UCD-T2DM rat · Verified applicability · 糖尿病模型（The review reports that fed or fasting blood glucose above 200 mg/dl is a commonly used criterion for diabetes onset in this model.；Verified applicability） · 2型糖尿病 (T2D)（How is diabetes defined and staged in the UCD-T2DM rat?; UCD-T2DM rats under regular chow or high-fat diet, with fed or fasting blood glucose monitoring.；Verified applicability）
    Akita mouse · Verified applicability · 糖尿病模型（The review reports that the Ins2 Akita mouse is a robust model of diabetic sympathetic autonomic neuropathy corresponding to other rodent models and humans.；Verified applicability） · 代谢疾病（Ins2Akita 小鼠：Ins2 显性突变致 β 细胞内质网应激，用于单基因糖尿病与糖代谢研究。；Verified applicability） · 糖尿病肾病 (DN)（Ins2 Akita 小鼠：1 型糖尿病白蛋白尿与肾小球病变；Verified applicability）
    high-fat diet plus streptozotocin-induced type 2 diabetes C57BL/6J mouse · Verified applicability · 糖尿病模型（Three groups: non-diabetic, diabetic, and diabetic treated with imeglimin；Verified applicability） · 2型糖尿病 (T2D)（Does aerobic exercise alleviate diabetic arterial remodeling through Sirt1?; Male C57BL/6J mice, 6 weeks old; CON, CON-Exe, T2DM and T2DM-Exe groups；Verified applicability） · 糖尿病肾病 (DN)（HFD+小剂量 STZ C57BL/6J 小鼠：ACR 升高、足细胞与纤维化终点；Verified applicability）
    streptozotocin-induced diabetes TTRhRen mouse · Verified applicability · 糖尿病模型（The review recommends TTRhRen mice with low-dose STZ as a hypertension-accelerated model of advanced diabetic nephropathy.；Verified applicability）
    high-fat diet plus low-dose streptozotocin-induced type 2 diabetes C57BL/6J mouse · Verified applicability · 糖尿病模型（Glucose tolerance and insulin sensitivity assessed by GTT and ITT；Verified applicability） · 代谢疾病（高脂饮食联合低剂量链脲佐菌素诱导的 2 型糖尿病模型，用于糖代谢、胰岛素抵抗及代谢并发症研究。；Verified applicability） · 2型糖尿病 (T2D)（How chromatin accessibility, transcript isoforms and RNA modifications are remodeled in diabetic cardiomyopathy.; Whether HFD/STZ mice develop diabetic cardiomyopathy with transcriptional and epigenetic remodeling.；Verified applicability）
    db/db C57BLKS mouse · Verified applicability · 糖尿病模型（Male C57BL/KsJ-db/db mice examined at 8, 16 and 24 weeks of age with db/+ littermate controls.；Verified applicability） · 2型糖尿病 (T2D)（Which renal and metabolic abnormalities develop in db/db mice; db/db mouse kidney and urine at 12 weeks；Verified applicability） · 糖尿病肾病 (DN)（C57BLKS 背景 db/db 小鼠：尿白蛋白/ACR、肾小球系膜基质扩张与 GBM 增厚的 2 型糖尿病肾病模型；Verified applicability）
    Goto-Kakizaki rat · Verified applicability · 糖尿病模型（GK rats were used as a spontaneous non-obese model of type 2 diabetes.；Verified applicability） · 代谢疾病（Goto-Kakizaki 大鼠：非肥胖型自发 2 型糖尿病大鼠，用于糖代谢与胰岛功能研究。；Verified applicability） · 2型糖尿病 (T2D)（Does resveratrol improve glucose tolerance, tissue lipid handling and pancreatic islet structure in Goto-Kakizaki rats?; GK rats；Verified applicability） · 糖尿病肾病 (DN)（GK 大鼠：非肥胖型 2 型糖尿病肾损伤（模型综述推荐的白蛋白尿/病理读出）；Verified applicability）
    ob/ob C57BL/6 mouse · Verified applicability · 糖尿病模型（ob/ob mice are severely obese and insulin resistant but do not fully reproduce human T2D.；Verified applicability） · 2型糖尿病 (T2D)（The review evaluates monogenic obesity models for T2D.; Published ob/ob mouse studies.；Verified applicability）
    Zucker diabetic Sprague-Dawley (ZDSD) rat · Verified applicability · 糖尿病模型（The review concludes that the ZDSD rat progresses from prediabetes to overt diabetes and is an advantageous preclinical model of type 2 diabetes.；Verified applicability） · 代谢疾病（ZDSD 大鼠：Zucker 糖尿病 Sprague-Dawley 品系，用于肥胖合并 2 型糖尿病研究。；Verified applicability） · 2型糖尿病 (T2D)（Which rodent models and endpoints have been used to study obesity, type 1 diabetes, type 2 diabetes and diabetic peripheral neuropathy, and what are their limitations?; Zucker diabetic Sprague-Dawley rats.；Verified applicability）
    high-fat diet plus low-dose streptozotocin-induced type 2 diabetes rodent · Verified applicability · 糖尿病模型（The review reports that high caloric feeding combined with low-dose STZ is used to overcome low penetrance of HFD-induced diabetes.；Verified applicability） · 2型糖尿病 (T2D)（How can diet and low-dose streptozotocin be combined to model type 2 diabetes?; rodents fed high caloric diets with low-dose STZ；Verified applicability）
    streptozotocin-induced diabetes C57BL/6 mouse · Verified applicability · 糖尿病模型（High-dose streptozotocin-induced insulin-deficient diabetic mice were used to study diabetic wound healing and the PNS mechanism; this is not a type 2 diabetes model.；Verified applicability） · 糖尿病肾病 (DN)（STZ 糖尿病 C57BL/6 小鼠：HMGB1/系膜与小管间质终点；Verified applicability）
    NOD 自发性1型糖尿病模型（文献参考） · Verified applicability · 糖尿病模型（自身免疫性 1 型糖尿病自发进程与免疫干预研究的文献参考模型（NOD）；Verified applicability）
    STZ 诱导糖尿病模型 · Verified applicability · 2型糖尿病 (T2D)（STZ 诱导糖尿病模型；Candidate (not internally validated)） · 糖尿病模型（STZ 模型用于糖尿病机制及干预研究；适用性依据为文献报道。；Verified applicability）
    ob/ob (Lep^ob) · Verified applicability · 2型糖尿病 (T2D)（ob/ob 模型用于肥胖、胰岛素抵抗与2型糖尿病相关代谢研究，糖尿病表型受遗传背景影响。；Verified applicability） · 糖尿病模型（ob/ob 模型用于糖尿病机制及干预研究；适用性依据为文献报道。；Verified applicability） · 代谢疾病（糖尿病及代谢疾病机制研究中的遗传性肥胖糖尿病参考模型（ob/ob）；Verified applicability）
    db/db (Lepr^db) · Verified applicability · 2型糖尿病 (T2D)（db/db 模型用于肥胖相关胰岛素抵抗和2型糖尿病研究，适用性受遗传背景影响。；Verified applicability） · 糖尿病肾病 (DN)（C57BLKS 背景 db/db 模型用于糖尿病肾病研究，仅部分重现人类疾病特征。；Verified applicability） · 代谢疾病（db/db 模型用于肥胖及代谢异常研究，适用性受遗传背景影响。；Verified applicability） · 糖尿病模型（db/db 模型用于糖尿病机制及干预研究；适用性依据为文献报道。；Verified applicability）

Some related records could not be loaded.

Reagent consultation